Dulaglutide vs Eloralintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Trulicity
An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Also: GSBR-1290, Structure GSBR-1290
A next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.
Key Comparison Insights
- Dulaglutide is FDA approved, while Eloralintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Dulaglutide has stronger research evidence (FDA Approved) compared to Eloralintide (Phase 2 Clinical Trial).
Detailed Comparison
| Attribute | Dulaglutide | Eloralintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dulaglutide consists of two GLP-1 analogs linked to a modified human IgG4 Fc fragment. This structure extends half-life to about 5 days, allowing weekly dosing. Works through standard GLP-1 receptor activation. | Eloralintide is a small-molecule, non-peptide GLP-1 receptor agonist that mimics the action of GLP-1. Unlike traditional peptide-based GLP-1 agonists, it is orally bioavailable without requiring absorption enhancers. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. |
| Common Dosing | 1.5-4.5 mg weekly Once weekly | 120-240mg once daily (oral) Once daily |
| Administration | Subcutaneous injection weekly | Oral tablet |
| Typical Duration | Long-term / chronic use | 36 weeks in Phase 2 trials |
| Best Time to Take | Before bed or morning (fasted) | - |
Possible Side Effects May vary by individual |
|
|
| Research Summary | AWARD program showed significant A1C reduction and weight loss. REWIND trial demonstrated cardiovascular benefits in broader diabetic population. Generally shows 3-5% weight loss in trials. | Phase 2 GSBR-1290-004 trial (2024) showed up to 14.4% body weight reduction at 36 weeks with the highest dose. Results showed a favorable GI tolerability profile compared to injectable GLP-1 agonists, with lower rates of nausea and vomiting. The oral small-molecule design eliminates the need for injections, potentially improving patient adherence. Structure Therapeutics reported positive Phase 2b results with dose-dependent weight loss across multiple cohorts. |
Frequently Asked Questions: Dulaglutide vs Eloralintide
What is the difference between Dulaglutide and Eloralintide?
Dulaglutide is a weight loss peptide that an fda-approved weekly glp-1 receptor agonist for type 2 diabetes. fused to an fc antibody fragment for extended duration of action. Eloralintide is a weight loss peptide that a next-generation oral glp-1 receptor agonist developed by structure therapeutics (now ventyx biosciences). shows comparable weight loss to injectable glp-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dulaglutide or Eloralintide?
Neither is universally "better" - the choice depends on your specific goals. Dulaglutide is typically used for weight loss purposes, while Eloralintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dulaglutide and Eloralintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dulaglutide and Eloralintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.